Pemetrexed-induced acute kidney injury leading to chronic kidney disease

Clinical Nephrology

Volumn 82, Issue 6, 2014, Pages 402-406

  Chauvet, Sophie ^a,b   Courbebaisse, Marie ^a   Ronco, Pierre ^a,b   Plaisier, Emmanuelle ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

Acute tubular necrosis; Antifolate agent; Chronic kidney disease; Pemetrexed

Indexed keywords

CISPLATIN; CREATININE; DICLOFENAC; FOLINIC ACID; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; BRUSH BORDER; CANCER PATIENT; CANCER RECURRENCE; CASE REPORT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EYELID EDEMA; FEMALE; FIBROSING ALVEOLITIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; LABORATORY TEST; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; MIDDLE AGED; NEPHROTOXICITY; NON SMALL CELL LUNG CANCER; PAIN; PHYSICAL EXAMINATION; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA; RISK FACTOR; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; EDEMA; EYELID DISEASE; KIDNEY TUBULE NECROSIS; LUNG NEOPLASMS; TUMOR RECURRENCE;

ACUTE KIDNEY INJURY; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; EDEMA; EYELID DISEASES; FEMALE; HUMANS; KIDNEY TUBULAR NECROSIS, ACUTE; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEMETREXED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84920281216     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107921     Document Type: Article

References (22)

1. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol. 2009; 4: 1275-1283.
2. Launay-Vacher V, Isnard-Bagnis C, Janus N, Karie S, Deray G. [Chemotherapy and renal toxicity]. Bull Cancer. 2008; 95 FMC Onco: F96-F103.
3. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007; 6: 404-417.
4. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol. 2000; 11: 1335-1341.
5. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist. 2004; 9: 482-488.
6. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs. 2006; 24: 37-77.
7. Mita AC, Sweeney J, Baker SD, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher A, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK. Takimoto. Phase I and Pharmacokinetic Study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006; 24: 252-262.
8. Molina JR, Adjei AA. The role of Pemetrexed (Alimta, LY231514) in lung cancer therapy. Clin Lung Cancer. 2003; 5: 21-27.
9. Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol. 2003; 21: 4066-4069.
10. Vootukuru V, Liew YP, Nally JV Jr. Pemetrexedinduced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer. Med Oncol. 2006; 23: 419-422.
11. Pena-Porta JM. Vicente De Vera Floristan, BuesoInglan P Florian Jerico J. Acute renal failure associated with pemetrexed (Alimta). Nefrologia. 2009; 29: 610-611.
12. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute tubular necrosis and interstitial nephritis during pemetrexed therapy. Case Rep Oncol. 2009; 2: 53-56.
13. Kurata T, Tamura K, Okamoto I, Satoh T, Nakagawa K, Fukuoka M. Pemetrexed-induced edema of the eyelid. Lung Cancer. 2006; 54: 241-242.
14. Schallier D, Decoster L, Fontaine C, De Grève J. Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res. 2010; 30: 5185-5188.
15. Guhl G, Diaz-Ley B, Sanchez-Perez J, Jimenez U, Garcia-Diez A. Pemetrexed-induced edema of the eyelid. Lung Cancer. 2010; 69: 249-250.
16. Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011; 58: 817-820.
17. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006; 11: 694-703.
18. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999; 106: 459-465.
19. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics. 2005; 15: 277-285.
20. Launay-Vacher V, Izzedine H, Karie S, Hulot JS, Baumelou A, Deray G. Renal tubular drug transporters. Nephron, Physiol. 2006; 103: 97-106.
21. El Sheikh A, Van Den Heuvel J, Koendrink J, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007; 320: 229-235.
22. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T, Sugiyama Y, Kondo T et al. Species difference in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human Kidney Slices. J Phar ExpTher. 2007; 322: 1162-1170.